Senthil Gobalakrishnan1, Sylvia Santhakumari Asirvatham2, Venkatraman Janarthanam3. 1. Assistant Professor, Department of Pharmacology, Sri Manakula Vinayagar Medical college , Pondicherry, India . 2. Professor, Department of Pharmacology, Raja Muthia Medical College , Chidambaram, India . 3. Assistant Professor, Department of Pathology, Sri Manakula Vinayagar Medical college , Pondicherry, India .
Abstract
INTRODUCTION: Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis associated conditions, such as Coronary Heart Disease (CHD), ischaemic cerebrovascular disease and peripheral vascular disease. Though there are hypolipidemic drugs available, the search for a more efficacious hypo lipidemic agent was always going on. AIM: To study the effect of Silybin on lipid profile in Hypercholesterolaemic rats. MATERIALS AND METHODS: After grant of permission from animal ethics committee, the animals were divided into four groups of eight each (normal control, Experimental control with High cholesterol diet, High cholesterol diet + Silybin 300mg, High cholesterol diet + Silybin 600mg). At the end of 60 days the animals in all the groups were subjected to overnight fasting followed by plasma and liver biochemical analyses. STATISTICAL ANALYSIS: The data were analysed by ANNOVA followed by Duncan's multi range test and the value of p≤0.05 was used as the criterion for statistical significance. RESULTS: The rats fed on high cholesterol diet showed significant increase in serum total cholesterol, Triglycerides, LDL-C and VLDL-C. Treatment with Silybin significantly decreased serum total cholesterol (24%), Triglycerides (21%), LDL-C (24%) in a dose dependent manner. Rats treated with Silybin (300 and 600 mg/kg) showed significant increase in hepatic HDL -C and decrease in other lipid profiles. CONCLUSION: Treatment with Silybin significantly decreased both serum and hepatic total cholesterol, triglycerides, VLDL-C, LDL-C and increased HDL-C at both doses.
INTRODUCTION:Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis associated conditions, such as Coronary Heart Disease (CHD), ischaemic cerebrovascular disease and peripheral vascular disease. Though there are hypolipidemic drugs available, the search for a more efficacious hypo lipidemic agent was always going on. AIM: To study the effect of Silybin on lipid profile in Hypercholesterolaemic rats. MATERIALS AND METHODS: After grant of permission from animal ethics committee, the animals were divided into four groups of eight each (normal control, Experimental control with High cholesterol diet, High cholesterol diet + Silybin 300mg, High cholesterol diet + Silybin 600mg). At the end of 60 days the animals in all the groups were subjected to overnight fasting followed by plasma and liver biochemical analyses. STATISTICAL ANALYSIS: The data were analysed by ANNOVA followed by Duncan's multi range test and the value of p≤0.05 was used as the criterion for statistical significance. RESULTS: The rats fed on high cholesterol diet showed significant increase in serum total cholesterol, Triglycerides, LDL-C and VLDL-C. Treatment with Silybin significantly decreased serum total cholesterol (24%), Triglycerides (21%), LDL-C (24%) in a dose dependent manner. Rats treated with Silybin (300 and 600 mg/kg) showed significant increase in hepatic HDL -C and decrease in other lipid profiles. CONCLUSION: Treatment with Silybin significantly decreased both serum and hepatic total cholesterol, triglycerides, VLDL-C, LDL-C and increased HDL-C at both doses.
Authors: W M Verschuren; D R Jacobs; B P Bloemberg; D Kromhout; A Menotti; C Aravanis; H Blackburn; R Buzina; A S Dontas; F Fidanza Journal: JAMA Date: 1995-07-12 Impact factor: 56.272
Authors: S C Smith; S N Blair; M H Criqui; G F Fletcher; V Fuster; B J Gersh; A M Gotto; K L Gould; P Greenland; S M Grundy Journal: Circulation Date: 1995-07-01 Impact factor: 29.690
Authors: Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami Journal: Pharmaceuticals (Basel) Date: 2022-04-27